LnRiLWZpZWxke21hcmdpbi1ib3R0b206MC43NmVtfS50Yi1maWVsZC0tbGVmdHt0ZXh0LWFsaWduOmxlZnR9LnRiLWZpZWxkLS1jZW50ZXJ7dGV4dC1hbGlnbjpjZW50ZXJ9LnRiLWZpZWxkLS1yaWdodHt0ZXh0LWFsaWduOnJpZ2h0fS50Yi1maWVsZF9fc2t5cGVfcHJldmlld3twYWRkaW5nOjEwcHggMjBweDtib3JkZXItcmFkaXVzOjNweDtjb2xvcjojZmZmO2JhY2tncm91bmQ6IzAwYWZlZTtkaXNwbGF5OmlubGluZS1ibG9ja311bC5nbGlkZV9fc2xpZGVze21hcmdpbjowfQ==
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
AIFM3 Antibody
0.1 mg
Product Description
APO-4541
Background
AIFM3 Antibody: Apoptosis, also known as programmed cell death, plays major roles in development and normal tissue turnover in addition to tumor formation. Recently a protein similar to the apoptosis-inducing factor (AIF) was cloned and designated AIFL (also known as AIFM3). AIFM3 is expressed ubiquitously and is predominantly localized to the inner membranes of mitochondria. Unlike AIF, AIFM3 does not translocate to the nucleus upon induction of apoptosis. However, overexpression of AIFM3, like AIF, induced cytochrome c release from the mitochondria, cleavage of caspase 3, and ultimately apoptosis, indicating AIFM3 induces apoptosis through caspase activation. Multiple isoforms of AIFM3 are known to exist.
?
Description
Western blot analysis of AIFM3 in human brain tissue lysate with AIFM3 antibody at (A) 1 and (B) 2 ?g/mL.
?
?
?
?
?
?
?
?
?
?
?
?
Specifications
Additional Names
AIFM3 Antibody: Apoptosis-inducing factor mitochondrion-associated 3, AIFL
Disclaimer
This product is for research use only.
User Note
Optimal dilutions for each application to be determined by the researcher.
Immunogen
AIFM3 antibody was raised against a 16 amino acid synthetic peptide from near the center of human AIFM3.
Clonality/Clone
This is a polyclonal AIFM3 Antibody.
Formulation
Physical State: Liquid?
Concentration: 1 mg/mL
Purification
AIFM3 Antibody is affinity chromatography purified via peptide column.
Host
AIFM3 antibody was raised in rabbit.
Please use anti-rabbit secondary antibodies.
Application
AIFM3 antibody can be used for the detection of AIFM3 by Western blot at 1 – 2 ?g/mL.
Buffer
AIFM3 Antibody is supplied in PBS containing 0.02% sodium azide.
Blocking Peptide
Cat.No. ZP-4541 – AIFM3 Peptide
Storage
AIFM3 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Protein GI Number
74732608
Protein Accession Number
Q96NN9
Reference
Jin Z and El Deiry WS. Overview of cell death signaling pathways. Cancer Biol. Ther.2004; 4:139-63
Xie Q, Lin T, Zhang Y, et al. Molecular cloning and characterization of a human AIF-like gene with the ability to induce apoptosis. J. Biol. Chem.2005; 280:19673-81.]
?
